Immunohistochemical detection of p53 and pp53 Ser392 in canine hemangiomas and hemangiosarcomas located in the skin

García‐Iglesias, M. J.; Cuevas-Higuera, Jose Luis; Bastida-Sáenz, Ana; García, María Gracia de Garnica; Polledo, L.; Perero, Paula; González-Fernández, Jorge; Fernández-Martínez, Beatriz; Pérez-Martínez, Claudia

doi:10.1186/s12917-020-02457-6

Cited by 8 publications

(13 citation statements)

References 49 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is important to highlight that TP53 mutations are important and frequently found in several cancer subtypes. García-Iglesias et al [ 20 ] found a high expression of the mutated TP53 gene associated with high Ki-67 proliferative activity in 25 dogs with cutaneous HSA, suggesting the association of this gene mutation with neoplastic development. Both studies included patients with dermal and hypodermic HSAs.…”

Section: Etiology and Epidemiologymentioning

confidence: 99%

“…Several studies have identified immunohistochemical markers for the diagnosis of HSA, including the Willebrand factor (FVIII), VEGF, bFGF, and claudin-5 [ 22 , 31 , 35 , 36 ]. In addition, García-Iglesias et al (2020) [ 20 ] demonstrated that CD117 immunoexpression (KIT) and Ki-67 index could be useful in differentiating between cutaneous HSA and hemangioma.…”

Section: Diagnosis and Stagingmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET

Nardi

Massoco

Fonseca-Alves

et al. 2023

Cancers

View full text Add to dashboard Cite

Hemangiosarcoma is a mesenchymal neoplasm originating in the endothelial cells of blood vessels; they can be classified as non-visceral and visceral types. Non-visceral hemangiosarcomas can affect the skin, subcutaneous tissues, and muscle tissues; visceral hemangiosarcomas can affect the spleen, liver, heart, lungs, kidneys, oral cavity, bones, bladder, uterus, tongue, and retroperitoneum. Among domestic species, dogs are most affected by cutaneous HSA. Cutaneous HSA represents approximately 14% of all HSA diagnosed in this species and less than 5% of dermal tumors, according to North American studies. However, Brazilian epidemiological data demonstrate a higher prevalence, which may represent 27 to 80% of all canine HSAs and 13.9% of all skin neoplasms diagnosed in this species. Cutaneous HSA most commonly affects middle-aged to elderly dogs (between 8 and 15 years old), with no gender predisposition for either the actinic or non-actinic forms. The higher prevalence of cutaneous HSA in some canine breeds is related to lower protection from solar radiation, as low skin pigmentation and hair coverage lead to greater sun exposure. Actinic changes, such as solar dermatosis, are frequent in these patients, confirming the influence of solar radiation on the development of this neoplasm. There are multiple clinical manifestations of hemangiosarcoma in canines. The diagnostic approach and staging classification of cutaneous HSAs are similar between the different subtypes. The definitive diagnosis is obtained through histopathological analysis of incisional or excisional biopsies. Cytology can be used as a presurgical screening test; however, it has little diagnostic utility in cases of HSA because there is a high risk of blood contamination and sample hemodilution. Surgery is generally the treatment of choice for dogs with localized non-visceral HSA without evidence of metastatic disease. Recently, electrochemotherapy (ECT) has emerged as an alternative therapy for the local ablative treatment of different neoplastic types; the use of radiotherapy for the treatment of dogs with cutaneous HSA is uncommon. There is greater consensus in the literature regarding the indications for adjuvant chemotherapy in subcutaneous and muscular HSA; doxorubicin is the most frequently used antineoplastic agent for subcutaneous and muscular subtypes and can be administered alone or in combination with other drugs. Other therapies include antiangiogenic therapy, photodynamic therapy, the association of chemotherapy with the metronomic dose, targeted therapies, and natural products. The benefits of these therapies are presented and discussed. In general, the prognosis of splenic and cardiac HSA is unfavorable. As a challenging neoplasm, studies of new protocols and treatment modalities are necessary to control this aggressive disease.

show abstract

Section: Etiology and Epidemiologymentioning

confidence: 99%

Section: Diagnosis and Stagingmentioning

confidence: 99%

Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET

Nardi

Massoco

Fonseca-Alves

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In the same study, TP53 mutations were detected in 35% of cutaneous tumors (12 out of 34). Other investigations have also reported frequent TP53 mutations in human angiosarcomas [7–9] . Collectively, these genetic studies strongly suggest that the PI3K, MAPK, and TP53 pathways play an important role in the development of angiosarcoma.…”

Section: Discussionmentioning

confidence: 52%

“…The rarity of angiosarcoma makes large genomic studies to identify pathologic driver mutations almost impossible. Nonetheless, recent sequencing studies have implicated the PI3K, MAPK, and TP53 pathways as key oncogenic mechanisms driving the development of angiosarcoma [6–10] . In 2019, Cao et al [21] detected somatic alterations in PIK3CA and PIK3R1 (the 85 kDa regulatory subunit of PI3K) in the tumor specimen of a 51-year-old female patient with primary splenic angiosarcoma.…”

Section: Discussionmentioning

confidence: 99%

Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma

Wan

Zhang

et al. 2021

Medicine

View full text Add to dashboard Cite

Angiosarcoma is a rare, highly aggressive malignant tumor originating from endothelial cells that line the lumen of blood or lymphatic vessels. The molecular mechanisms of scalp and face angiosarcoma still need to be elucidated. This study aimed to investigate the expression of phosphatase and tensin homolog (PTEN), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphorylated mitogen-activated kinase-like protein (pMAPK), and tumor protein p53 (TP53) in scalp and face angiosarcoma and to assess tumor tissue apoptosis.The expression and intracellular distribution of PTEN, PIK3CA, pMAPK, and TP53 proteins in 21 specimens of human scalp and face angiosarcoma and 16 specimens of human benign hemangioma were evaluated using immunohistochemistry. Tumor cell apoptosis was assessed by terminal deoxyribonucleotide transferase-mediated dUTP nick end-labeling staining.Significantly lower PTEN but higher PIK3CA, pMAPK, and TP53 immunostaining were detected in the angiosarcoma specimens than in the benign hemangioma specimens(P < .01). The angiosarcoma tissues exhibited significantly higher apoptosis indices than the benign hemangioma tissues (P < .01). The positive expression rates of PIK3CA, pMAPK, and TP53 were correlated with the degree of tumor differentiation in the human scalp and face angiosarcoma.The PI3K, MAPK, and TP53 pathways might be involved in angiosarcoma tumorigenesis in humans and may serve as therapeutic targets for the effective treatment of this malignancy.

show abstract

“…García–Iglesias et al. found that p53 and phosphorylated p53 serine were highly expressed in angiosarcoma [62] . Kiyohara et al.…”

Section: Discussionmentioning

confidence: 99%

Differences in potential key genes and pathways between primary and radiation-associated angiosarcoma of the breast

Wei

Yang

Gao

et al. 2022

Translational Oncology

View full text Add to dashboard Cite

Immunohistochemical detection of p53 and pp53 Ser392 in canine hemangiomas and hemangiosarcomas located in the skin

Cited by 8 publications

References 49 publications

Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET

Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET

Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma

Differences in potential key genes and pathways between primary and radiation-associated angiosarcoma of the breast

Contact Info

Product

Resources

About